RAPT Therapeutics (RAPT) Cash & Current Investments: 2020-2024
Historic Cash & Current Investments for Therapeutics (RAPT) over the last 5 years, with Sep 2024 value amounting to $97.9 million.
- Therapeutics' Cash & Current Investments fell 47.01% to $97.9 million in Q3 2024 from the same period last year, while for Sep 2024 it was $513.2 million, marking a year-over-year decrease of 41.05%. This contributed to the annual value of $158.9 million for FY2023, which is 36.22% down from last year.
- As of Q3 2024, Therapeutics' Cash & Current Investments stood at $97.9 million, which was down 14.75% from $114.8 million recorded in Q2 2024.
- Therapeutics' 5-year Cash & Current Investments high stood at $249.1 million for Q4 2022, and its period low was $97.9 million during Q3 2024.
- In the last 3 years, Therapeutics' Cash & Current Investments had a median value of $184.8 million in 2023 and averaged $178.1 million.
- As far as peak fluctuations go, Therapeutics' Cash & Current Investments soared by 75.81% in 2022, and later plummeted by 47.01% in 2024.
- Over the past 5 years, Therapeutics' Cash & Current Investments (Quarterly) stood at $111.5 million in 2020, then surged by 70.08% to $189.7 million in 2021, then surged by 31.33% to $249.1 million in 2022, then crashed by 36.22% to $158.9 million in 2023, then tumbled by 47.01% to $97.9 million in 2024.
- Its Cash & Current Investments stands at $97.9 million for Q3 2024, versus $114.8 million for Q2 2024 and $141.6 million for Q1 2024.